

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 28 Feb 2020 03:53:06 +0000  
**To:** Leonard Schleifer  
**Cc:** Erbeling, Emily (NIH/NIAID) [E]; Mascola, John (NIH/VRC) [E]; Cassetti, Cristina (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** RE: Regeneron COVID-19 update

Len:

Thanks for the note. Of course, we would be interested in working with you as you develop these antibodies.

Best regards,

Tony

---

**From:** Leonard Schleifer (b) (6)  
**Sent:** Thursday, February 27, 2020 3:25 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Cc:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)  
**Subject:** Regeneron COVID-19 update

Tony,

Obviously you are swamped and the country is likely safer for it! I wanted to be sure you were up to date on our efforts re COVID-19. (b) (4)

(b) (4)

We have had discussions with our partners at BARDA and have had contact with the White House.

(b) (4)

In the near future we will have a cocktail of antibodies ready for testing and we would be delighted to work with you and the NIH if that makes sense.

If you would like to discuss further, please call my cell (b) (6) at anytime.

Len

\*\*\*\*\* This e-mail and any attachment hereto, is intended only for use by the addressee(s) named above and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, any dissemination, distribution or copying of this email, or any attachment hereto, is strictly prohibited. If you receive this email in error please immediately notify me by return electronic mail and permanently delete this email and any attachment hereto, any copy of this e-mail and of any such attachment, and any printout thereof. Finally, please note that only authorized representatives of Regeneron